American Journal on Addictions
September 3, 2008
Li-Tzy Wu, Christopher L. Ringwalt, Paolo Mannelli et al.
30 citations
We investigated the prevalence, patterns, and correlates of past‐year DSM‐IV hallucinogen use disorders (HUDs) among past‐year users of MDMA and other hallucinogens from a sample of Americans 18 or older (n = 37,227). Users were categorized as MDMA users and other hallucinogen users. Overall, one in five (20%) MDMA users and about one in six (16%) other hallucinogen users reported at least one...
Journal of Psychopharmacology
January 21, 2008
Susana de Sola Llopis, Mónica Miguélez-Pan, Jordi Peña‐Casanova et al.
58 citations
There is important preclinical evidence of long lasting neurotoxic and selective effects of ecstasy MDMA on serotonin systems in non-human primates. In humans long-term recreational use of ecstasy has been mainly associated with learning and memory impairments. The aim of the present study was to investigate the neuropsychological profile associated with ecstasy use within recreational polydrug...
Journal of Psychoactive Drugs
March 1, 2007
Casey R. Guillot
26 citations
Due to potential serotonergic deficits, 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) may cause long-term mood disruptions in recreational Ecstasy users. The purpose of this review is to evaluate the evidence for a relationship between recreational Ecstasy use and higher levels of depressive symptoms. Eleven out of 22 studies initially have reported significantly higher depression scores...
Human Psychopharmacology: Clinical and Experimental
June 1, 2006
Sean P. Barrett, Christine Darredeau, Robert O. Pihl
276 citations
Abstract Simultaneous polysubstance use (SPU) is a common phenomenon, yet little is known about how various substances are used with one another. In the present study 149 drug‐using university students completed structured interviews about their use of various substances. For each substance ever used, participants provided details about the type, order and amount of all substances...
Drug and Alcohol Review
May 1, 2006
Michael Lyvers
41 citations
The controversy over possible MDMA-induced serotonergic neurotoxicity in human recreational ecstasy users is examined critically in light of recent research findings. Although the designs of such studies have improved considerably since the 1990s, the evidence to date remains equivocal for a number of reasons, including (1) inconsistent findings on the existence and reversibility of persistent...
Das Gesundheitswesen
May 1, 2006
Holger Siemann, Michael Specka, Fabrizio Schifano et al.
10 citations
The German pages of the Internet were searched for the presence of the hallucinogenic herbal drug Salvia divinorum, which is not dealt with in current addiction medicine or psychiatric text books. The investigation is part of the EU sponsored project "Psychonaut" as preparatory work for the development of an Internet-based early warning system. The first 100 websites of the search using "Salvia...
Journal of Psychopharmacology
March 30, 2006
Boris B. Quednow, Frank Jessen, Kai‐uwe Kühn et al.
105 citations
Chronic administration of the common club drug 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and non-human primates, and evidence suggests that recreational MDMA consumption may also affect the human serotonergic system. Moreover, it was consistently shown that abstinent MDMA users...
Journal of Psychopharmacology
March 1, 2006
Andy C. Parrott
139 citations
Many recreational ecstasy/MDMA users display neuropsychobiological de.cits, whereas others remain problem free. This review will investigate some of the drug and non-drug factors which in.uence the occurrence of these de.cits. Acute and chronic MDMA usage are both important. Intensive use within a session is often associated with more problems. In term of lifetime usage, novice users generally...
Journal of Psychopharmacology
March 1, 2006
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
179 citations
The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most...
Journal of Psychopharmacology
September 1, 2005
Alex Gamma, Daniel Brandeis, Ruven Brandeis et al.
36 citations
Substance abuse and associated externalizing disorders are characterized by behavioural disinhibition and low impulse control, with reduced neural inhibition postulated to be the common underlying brain mechanism. The P3 component of event-related potentials (ERPs) is a widely used neurophysiological measure thought to reflect inhibitory brain processes, but as yet has not been assessed in...